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Context: The cognitive side effects of medications with anticholinergic activity have been 
documented among older adults in a variety of clinical settings. However, there has been no 
systematic confirmation that acute or chronic prescribing of such medications lead to transient 
or permanent adverse cognitive outcomes.
Objective: Evaluate the existing evidence regarding the effects of anticholinergic medications 
on cognition in older adults.
Data sources: We searched the MEDLINE, OVID, and CINAHL databases from January, 
1966 to January, 2008 for eligible studies.
Study selection: Studies were included if the anticholinergic activity was systematically 
measured and correlated with standard measurements of cognitive performance. Studies were 
excluded if they reported case studies, case series, editorials, and review articles.
Data extraction: We extracted the method used to determine anticholinergic activity of 
medications and its association with cognitive outcomes.
Results: Twenty-seven studies met our inclusion criteria. Serum anticholinergic assay was the 
main method used to determine anticholinergic activity. All but two studies found an association 
between the anticholinergic activity of medications and either delirium, cognitive impairment 
or dementia.
Conclusions: Medications with anticholinergic activity negatively affect the cognitive per-
formance of older adults. Recognizing the anticholinergic activity of certain medications may 
represent a potential tool to improve cognition.
Keywords: anticholinergic activity, cognitive impairment, delirium, elderly
Clinical scenario
A 78-year-old Caucasian female presents to the emergency department (ED) with a 
chief complaint of shortness of breath, lethargy, and confusion. She was transported to 
the ED by her neighbor who assists with the history due to the patient’s current state of 
confusion. The patient lives alone in her own apartment in an independent senior living 
facility and has noted a decreased ability to complete her daily activities due to her 
shortness of breath and fatigue. Her past medical history is positive for hypertension, 
urinary incontinence, chronic obstructive pulmonary disease, gastroesophageal reflux 
disease, and atrial fibrillation. Her home medications include: ranitidine 150 mg by 
mouth twice daily, atenolol 50 mg by mouth daily, ipratropium inhaler 1–2 inhalations 
by mouth four times daily as needed, digoxin 0.125 mg by mouth daily, warfarin 3 mg 
by mouth daily, calcium carbonate/vitamin D 500 mg/200 IU by mouth twice daily, 
and Tyelonol PM® 500 mg/25 mg by mouth as needed for sleep. She is admitted for 
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chronic obstructive pulmonary disease (COPD) exacerbation 
and to rule out myocardial infarction. Her cognitive testing 
on admission reveals a Mini-Mental Status Examination 
(MMSE) score of 19/30 with deficits in orientation, attention, 
and recall. She scores positive on a Confusion Assessment 
Method (CAM) evaluation due to an acute change in mental 
status, disorganized thinking, and fluctuating attention.
Introduction
In 2005, there were more than 36 million Americans aged 65 
and older.1 This population is known to suffer from multiple 
chronic diseases, require numerous prescribed and over-the-
counter medications, and is at a higher risk of developing 
dementia.2-4 It is estimated that 20%–50% of the same cohort, 
including the four million with dementia, took at least one 
medication with some anticholinergic activities.3,5–8
The use of drugs with anticholinergic activity has been 
an integral part of the routine treatment of common condi-
tions such as asthma, urinary incontinence, and various 
psychiatric disorders. However, the adverse effects of these 
anticholinergics have been known for a long time including 
peripheral effects such as dry mouth and constipation, and 
central nervous system effects such as attention deficits and 
hallucinations.9 The central nervous system of older patients 
is very sensitive to the above adverse anticholinergic effects 
due to the significant decrease in cholinergic neurons or 
receptors in the brain of older adults, the reduction in hepatic 
metabolism and renal excretion of medications, and the 
increase in blood–brain barrier permeability.9
Many clinical researchers have recognized the impor-
tance of accounting for the risk of medications with central 
nervous system anticholinergic effects in the medical care of 
older patients, especially those with pre-existing cognitive 
disorders.3,9 However, there has been no systematic confirma-
tion that acute or chronic prescribing of such medications 
leads to transient or permanent adverse cognitive outcomes. 
Thus, we conducted this systematic review of the litera-
ture to identify the various methods used to determine the 
central anticholinergic effects of various medications and 
evaluate the impact of such activities on cognitive function 
of older adults.
Methods
search strategies and study selection
We searched the MEDLINE database using the search 
terms “cholinergic antagonists” combined with “delirium, 
dementia, amnestic, cognitive disorders.” We limited our 
search to the English language and human studies published 
between January 1966 and January 2008. In order to identify 
pertinent studies, we scanned titles and abstracts from each 
retrieved citation. Publications that appeared to be irrelevant 
on the basis of the study population and methods as indicated 
in the title and abstract were discarded. We were also able to 
retrieve additional pertinent publications using the reference 
lists from identified articles.
Inclusion criteria
We included all cross-sectional, case control, and retrospective 
or prospective observational cohort studies that evaluated the 
anticholinergic activity of medications and their impact on the 
cognitive function of older adults. We excluded case study, 
case series, editorial, and review articles.
Data extraction and synthesis
We extracted data from each study that met our inclusion 
criteria into a pre-defined table that included: citation, anticho-
linergic activity measurement method, association between 
anticholinergics and cognitive impairment, total number of 
patients, and baseline demographics (eg, age, gender). Each 
article was critically evaluated in six categories for internal 
validity. Articles were evaluated on the parameters of the 
type of data included, adjustments for confounders, attrition 
rates, use of standardized cognitive assessment measures, 
and the presence of selection and recall bias. Each parameter 
evaluating internal validity was awarded a score of  “1” if the 
study sufficiently met appropriate criteria and “0” if criteria 
were not met. Critical appraisal scores were then tabulated 
and correlated with a rating of “poor” if the appraisal score 
was 0–2; “fair” if the appraisal score was 3–4; and “good” 
if the score was 5–6. The critical appraisal was carried out 
by three clinical researchers (NC, MB, TL).
Results
Our search strategies revealed 258 potential articles from 
MEDLINE. However, after scanning the titles and the 
abstracts, we excluded 217 studies because they did not meet 
our inclusion criteria. An additional 20 of the remaining 
41 articles were excluded because they were reviews, case 
reports, or case series. From the reference lists of the iden-
tified articles we were able to find six additional pertinent 
publications (see Figure 1).
In total, we found 27 studies that have investigated the 
cognitive burden of drugs with anticholinergic properties 
(see Table 1). All but seven studies were conducted among a 
heterogeneous group of participants in the United States. The 
remaining non-US studies were conducted among French, 
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Canadian, German, and Portuguese patients, but published in 
the English language. The majority of the studies included in 
this review took place in a hospitalized or nursing home popu-
lation (n = 18), with the remaining studies (n = 9) evaluating 
ambulatory patients. Of the 27 studies, 13 were designed as 
cross-sectional, six studies were case-control, and eight were 
prospective or retrospective cohort studies.
The anticholinergic activity of medications was evaluated 
using the serum anticholinergic activities assay (SAA) or 
the practitioner’s knowledge of a list of drugs with known 
anticholinergic effects (see Table 2). SAA was the main 
method to determine anticholinergic activity in 17 studies. 
SAA is usually measured using a radio receptor competitive 
binding assay developed by Tune and Coyle.10 The SAA 
estimates anticholinergic activity generated not only from 
medications, but also from endogenous factors as a result 
of stress or hyperthermia.11 The other remaining studies 
combined clinical knowledge with drug lists to determine 
the anticholinergic activity of certain medications.
Acute anticholinergic effect  
on cognition
Delirium (acute and severe cognitive impairment) was 
diagnosed clinically using the DSM-IV criteria or using 
their derivatives, such as the Confusion Assessment Method 
(CAM), or its counterpart validated in the critically-ill popu-
lation, the CAM-ICU. The CAM or CAM-ICU is a highly 
sensitive and specific method that evaluates subjects for the 
presence of four items: acute onset of cognitive changes 
fluctuating in course, inattention, disorganized thinking, and 
altered level of consciousness.36 The presence of the first two 
items and any of the third or fourth items determines the 
diagnosis of delirium. Other tools evaluating concentration, 
wakefulness, orientation, perception, and sleep disturbances 
(Saskatoon Delirium Checklist [SDC]) were used to evalu-
ate delirium. The SDC11 and Delirium Symptoms Interview 
(DSI)37 were both validated tools developed from the DSM 
criteria to measure cognitive deficits.
Thirteen studies evaluated the impact of anticholinergic 
on delirium, with eleven studies identifying a positive asso-
ciation between the use of such medicines and delirium. 
Delirium episodes experienced by study participants occurred 
at any point in the observation period(commonly the duration 
of inpatient admission). Few studies evaluated sequential 
blood samples to measure changes in SAA over time. Nearly 
70% of the studies included in our analysis used SAA as the 
method for evaluating anticholinergic activity and 70% used 
either CAM or DSM criteria for evaluating delirium.
A recent study included in the analysis reported by 
Plaschke and colleagues evaluated a critically-ill population 
for the correlation of SAA or electroencephalography (EEG) 
with delirium.32 The authors report that a higher SAA value 
was identified in the delirious cohort, though this did not 
correlate with a difference in the risk of developing delirium 
in the ICU. Additionally, an article published in 1994 by 
Marcantonio and colleagues failed to draw a correlation 
between anticholinergic and postoperative delirium risk, 
though the anticholinergic exposure was only documented 
in 9% of the study population.24
Chronic anticholinergic effect  
on cognition
Chronic cognitive deficit was defined as mild cognitive impair-
ment, worsening dementia or new diagnosis of dementia, or 
global decline in cognition not caused by delirium. Cognitive 
performance was evaluated using the MMSE in most studies 
included in this review and found an association between 
the use of anticholinergic and cognitive performance as 
determined by the MMSE (Table 3). This screening tool 
for cognition evaluates different areas of cognition such as 
orientation, memory, recall, attention, and language. Any score 
above 24, out of a possible score of 30, is considered normal, 
while a score below 24 suggests a cognitive impairment.38 
A modified version of the MMSE, the telephone interview for 
cognitive status (TICS_, has also been also used. The TICS 
is as reliable and valid as the MMSE.39
Medline search result: 258 articles 
↓→ Excluded after scanning titles or abstracts:  217 
Relevant studies: 41 
↓→ Excluded reviews, case-reports, case-series:  20 
Included studies: 21 
↓← Included from reference lists:  6 
Total studies: 27 
Figure 1 selection process for study inclusion.
Clinical Interventions in Aging 2009:4228
Campbell et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Few studies evaluated for any long-term (12 months) 
impact on cognitive function in patients exposed to anticholin-
ergic. Ancelin and colleagues12 provided one of the few studies 
evaluating the impact of anticholinergic over time. This study 
included a French population without baseline cognitive defi-
cits and found an increased risk of mild cognitive impairment 
at the one-year follow-up based on criteria established by the 
Stockholm consensus group. However, at eight years of follow-
up the authors did not find an increased risk in the diagnosis of 
dementia (DSM-III) between consistent users of anticholinergic 
and nonusers. Another study by Lu and colleagues22 revealed 
no impact of anticholinergic exposure on cognition among 
a group of patients with baseline cognitive impairment at 
one year, though a significant decrease in cognitive function at 
two years was noticed in those using anticholinergics.
Clinical interpretation of data 
synthesis
Our systematic evidence review of 27 studies found a consistent 
association between the use of anticholinergic and cognitive 
Table 1 Clinical studies evaluating anticholinergic activity
Reference Design Setting Sample size/Mean age Critical appraisal*
Ancelin et al12 Longitudinal cohort 63 general practices 372/80 good
Bottigi et al13 Longitudinal cohort Patients from Aging Alzheimer’s  
Disease Research Center
592/73 Fair
Caeiro et al14 Case-control stroke patients from neurology 74/65 good
Chew et al15 Cross-sectional Psychiatric and geriatric clinic  
inpatients
26/83.6 Fair
Flacker et al16 Cross-sectional Acutely ill medical inpatients 67/85 good
Flacker et al17 Cross-sectional nursing home residents with  
fever
22/88 good
golinger et al18 Longitudinal cohort surgical Intensive care unit 25/58 Poor
han et al19 Longitudinal cohort hospitalized patients with  
delirium
278/83 good
hilmer et al20 Cross-sectional Community-based 3075/73 good
Lechevalier et al21 Cross-sectional Community-based 1780/77 good
Lu et al22 Longitudinal cohort Community-based 69/76 good
Mach et al23 Case-control VA hospital medical units 22/71 Fair
Marcantonio et al24 Cross-sectional Post-surgical patients 91/73 good
Miller et al25 Longitudinal cohort surgical patients 30/67 good
Minzenberg et al26 Cross-sectional Outpatients from VA medical 
center
106/40 Fair
Mondimore et al27 Cross-sectional Post-eCT inpatients 20/ 49 Fair
Mulsant et al6 Cross-sectional Community patients 201/78 good
Mussi et al28 Cross-sectional geriatric inpatients 61/79 Fair
nebes et al29 Cross-sectional Psychiatric and geriatric inpatients 36/69 Fair
nebes et al30 Cross-sectional Community based 134/75 Fair
Patten et al31 Case-control Psychiatric inpatients 425/65 Fair
Plaschke et al32 Longitudinal cohort Medical and surgical intensive  
care unit with delirium
37/64 Fair
Roe et al33 Case-control Community-based 836/75 Fair
Rovner et al34 Cross-sectional nursing home patients 22/81 Fair
Thienhaus et al35 Case-control Psychiatric and geriatric  
inpatients
28/65 Fair
Tollefson et al5 Case-control nursing home patients 34/79 good
Tune et al10 Longitudinal cohort Cardiac surgery patients 29/55 Fair
Abbreviations: VA, Veteran Administration; eCT, electro-convulsive therapy.
Notes: *Articles were appraised on the following criteria: inclusion of longitudinal data; adjustments for age, gender, baseline cognition, or other relevant parameters; attrition 
rate 40%; use of standardized measurements for cognition and delirium; minimum selection bias; and minimum recall bias.
Clinical Interventions in Aging 2009:4 229
Cognitive impact of anticholinergicsDovepress
submit your manuscript | www.dovepress.com
Dovepress 
impairment in older adults, including delirium. Our findings 
were similar to a review of 80 studies that was conducted by 
Dyer and colleagues40 that found a positive association between 
the use of anticholinergic drugs and postoperative delirium. 
Furthermore, Tune and colleagues also correlated delirium 
and confusional states in demented patients as a result of 
anticholinergic activities.10 The authors noted that this adverse 
effect may not arise exclusively from an individual agent 
with strong anticholinergic effects, but as an accumulation of 
multiple medications with varying degrees of anticholinergic 
effects. Similarly, the anticholinergic effects seem not to be 
related to the dosage of each individual drug, identifying the 
role of other factors in the development of cognitive deficits.41 
The presence of multiple baseline risk factors as well as the 
role of multiple neurotransmitter systems in the development 
of d elirium or cognitive impairment has been previously 
described.42
The finding of this systematic review indicates the 
burden of anticholinergic has consistently been shown to 
negatively associate with cognitive performance. All but 
two studies31 included in this review support the association 
of anticholinergic use and worsening cognitive performance 
either through an acute (delirium) or chronic (mild cognitive 
impairment) impact. The long-term effect of anticholinergics 
on cognition requires further analysis, as few studies 
adequately quantified exposure to anticholinergics and 
correlated this exposure to long-term risks of developing a 
neurodegenerative dementing disorder such as Alzheimer 
disease.
The studies included in this evaluation draw a consistent 
correlation between SAA and worsening performance 
on cognitive testing. Throughout the studies evaluated in 
this review, investigators discovered minimal changes in 
global measures of cognitive function with exposure to 
anticholinergics, and instead identified deficits in processing 
speed, psychomotor performance, concentration/attention, 
problem solving and language skills. Delirium was frequently 
identified by disorientation, altered consciousness, disorga-
nized thinking, and fluctuating alertness. Variable deficits in 
recall were identified, with some articles describing deficits in 
verbal or narrative recall, with others identifying no change 
in recall abilities. The significance of this comparison is 
that in a clinical setting many practitioners rely on global 
measures to evaluate cognitive performance and therefore 
may not accurately identify a decline in cognitive function 
when evaluating exposure to anticholinergics.
Most studies identified in our review have used the 
in vitro SAA, while few studies have used drug lists coupled 
with clinical judgment.6 All of these different methods have 
limitations, such as the inability to assess anticholinergic 
effects of each individual drug or to determine their potential 
synergistic effects when combined. Although higher levels 
of SAA has been correlated with poor cognitive function in 
several previous studies, conflicting data exists that makes 
Table 2 Association between serum anticholinergic activities and 
cognition
Reference CI Delirium
Ancelin et al12 + 
(stockholm)
n/A
Chew et al15* + 
(MMse, sIB)
n/A
Flacker et al16 n/A + 
(CAM, DsI)
Flacker et al17 n/A + 
(CAM)
golinger et al18 n/A + 
(DsM-III)
Mach et al23 n/A + 
(DsM-III-R)
Miller et al25 - 
(MMse)
+ 
(sDC)
Mondimore et al27 + 
(MMse)
n/A
Mulsant et al6 + 
(MMse)
n/A
Mussi et al28 n/A + 
(CAM)
nebes et al29 + 
(DsM-IV)
n/A
nebes et al30 + 
(Verbal n Back test)
n/A
Plaschke et al32 n/A - 
(CAM-ICU)
Rovner et al34* + 
(MMse, DsM-III)
n/A
Thienhaus et al35* + 
(MMse)
n/A
Tollefson et al5* + 
(MMse, BCRs, WMs)
+ 
(sDC)
Tune et al10 n/A + 
(Clinical)
Abbreviations: CI, cognitive impairment, includes mild cognitive impairment 
(MCI), or worsening function in those with baseline diagnosis of CI;  “+”: statistically 
significant association;  “-”: no significant association; “N/A”: not assessed; Stockholm, 
stockholm consensus group criteria for diagnosing mild cognitive impairment; sAA, 
serum anticholinergic activity; MMse, Mini-Mental state exam; sIB, severe impairment 
battery;   TMT,   Trail Making Test;   WLMT,   Word List Memory  Test; BCRs, Brief Cognitive 
Rating scale;   WMs,   Wechsler Memory scale; sDC, saskatoon Delirium Checklist; 
CAM, Confusion  Assessment Method; DsI, Delirium symptom Interview; DI, Delirium 
Index; IsT, Isaacs’ set Test; BVRT, Benton Visual Retention Test; DRs, Dementia Rating 
scale; DssT, Digit symbol substitution Test (derived from the WMs).
Note: *Indicates the study population had baseline cognitive impairment.
Clinical Interventions in Aging 2009:4230
Campbell et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
interpretation of the absolute SAA value difficult. Similarly, 
the complexity of the testing procedure, along with the inter-
mittent availability, limits the widespread acceptance as a 
biomarker or predictor of delirium. Many existing medication 
scales compute a total score of different drugs to determine 
the anticholinergic burden, suggesting that special attention 
should be paid not only to individual drug score, but also 
to the accumulated anticholinergic effects of all medica-
tions taken by the patient. Carnahan and colleagues41 have 
established a tool, the anticholinergic drug scale (ADS), 
divided in an ordinal fashion from 0 to 3, with 0 signifying 
no known anticholinergic activity, and 3 signifying marked 
anticholinergic activity. They found that ADS total scores 
were significantly associated with SAA. However, Thomas 
and colleagues failed to prove a correlation between SAA 
and a clinical diagnosis of delirium in older patients ( age 
80 years) with acute illness.43 Their results suggest the SAA 
is limited to peripheral activity, not central anticholinergic 
effects that may impact cognition.
The main limitation of this review is in the selection of 
studies with different designs and settings that contribute to 
the common conclusion. This review also bears limitations 
inherent to each study design, whether it is a cross-sectional, a 
case-control or a longitudinal study. Given the heterogeneity 
in the included studies and populations, baseline confounders 
such as cognitive impairment, past medical history and 
reason for admissions could not be evaluated and may impact 
results. The heterogeneity in study populations of the included 
studies may have significantly affected results. It is well 
documented that endogenous cholinergic neurotransmitter 
shifts may impact cognition,44,45 as well as normal responses 
to stress that may play a role in cognitive testing. Similarly, 
reporting mechanisms for the medications evaluated in the 
included studies was inconsistent, making the generation 
of a comprehensive, clinically useful list of anticholinergic 
medications impractical from this data set. Although central 
anticholinergic activity is most relevant in the development 
of delirium, cognitive impairment, or dementia, no study 
stratified medications by peripheral or central activity.
Through our search strategy, it is possible to miss a small 
number of studies that are unpublished. All but two studies 
assessed either acute cognitive impairment or delirium, with 
few studies measuring long-term effects on cognition. More-
over, methods used to diagnose delirium were not consistent 
throughout the included studies. The diagnostic criteria for 
delirium have evolved over time; thus the reviewed studies 
present a variety of methods to measure the diagnosis. 
Despite these limitations, this study is the first comprehen-
sive review of the measurement and cognitive impact of 
anticholinergic medications.
Gaps in the literature
Despite the associations that have been previously described 
regarding the impact of anticholinergics on cognitive 
function, several gaps in the existing literature can still 
be identified. First, our existing literature support for the 
association of anticholinergics and cognitive impairment 
lacks randomized, prospective clinical trials that describe a 
presumed difference in relevant outcomes. It remains to be 
sufficiently determined what outcomes should be expected if 
a reduction in anticholinergic activity is achieved in various 
populations with and without cognitive impairment. One 
might speculate that frequency and severity of acute or 
chronic mental status changes be reduced when the burden 
of anticholinergic medications is reduced, though the extent 
or duration of exposure minimization required to achieve a 
clinically significant impact remains to be delineated.
Table 3 Association between anticholinergic activity assessed by 
expert-based drug list and cognition
Reference CI Delirium
Bottigi et al13 + 
(MMse, TMT, WLMT)
n/A
Caeiro et al14 n/A + 
(DsM-IV-TR)
han et al19 n/A + 
(DI)
hilmer et al20 + 
(DssT)
n/A
Lechevalier et al21 + 
(MMse, BVRT, IsT)
n/A
Lu et al22* + 
(MMse, DRs)
n/A
Marcantonio et al24 n/A - 
(CAM)
Minzenberg et al26 + 
(WMs)
n/A
Patten et al31 n/A + 
(DsM-IV)
Roe et al33* + 
(Initiation of Donepezil therapy)
n/A
Abbreviations: CI, cognitive impairment, includes mild cognitive impairment (MCI), 
or worsening function in those with baseline diagnosis of CI;  “+”: statistically significant 
association;  “-”: no significant association;  “N/A”: not assessed; MMSE, Mini-Mental 
state exam; TMT, Trail Making Test; WLMT, Word List Memory Test; DsM-IV-TR, 
Diagnostic and Statistical  Manual of Mental Disorders, 4th edition; WMs, Wechsler 
Memory scale; CAM, Confusion  Assessment Method; IsT,  Isaacs’ set Test; BVRT, Benton 
Visual Retention Test; DRs, Dementia Rating scale; DssT, Digit symbol substitution 
Test (derived from the WMs).
Note: *Indicates the study population had baseline cognitive impairment.
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Secondly, the correlation of exposure to anticholinergics 
and health-related outcomes remains to be described. Many 
literature sources included in this review have drawn asso-
ciations between anticholinergics use and cognitive impair-
ment; however, no data source has evaluated an impact on 
hospitalization rates, emergency department visits, duration 
of hospital stay, overall quality of life, or even mortality.
Finally, long-term exposure to medications with anticho-
linergic activity was not evaluated in a majority of the studies. 
The impact of anticholinergics on cognitive impairment was 
often limited to short-term exposure, with limited assessment 
of medication regimens or SAA values. The impact of long-
term exposure to medications with anticholinergic medica-
tions remains to be sufficiently examined, as in the PAQUID 
study of community-dwelling elders in southern France.21 
Similarly, a recent study by Boustani and colleagues suggests 
an increased risk of incident cognitive impairment in Afri-
can-Americans consistently using H-2 receptor antagonists 
over a five-year observation period.46 This warrants further 
study into the impact of chronic exposure to anticholinergic 
medications, the potential for this exposure to influence 
cognition over time, and the extent of exposure required to 
induce adverse cognitive outcomes.
We suggest the logical management of anticholinergics 
use as described in Figure 2. As illustrated in this review, 
the elderly population, and specifically those experiencing 
Patients >65 years taking at least one
anticholinergic medication at presentation
to a medical provider  
Acute care environment (surgery,
emergency department, critical)
care, general hospital admission)  
Consider holding anticholinergic
medications; replace anticholinergics
with alternative treatment, 
re-evaluate delirium within 24 hours,
and refer to outpatient cognitive
assessment after discharge
  
Delirium is present 
Ambulatory clinical environment 
Dementia or mild cognitive
impairment is present 
Consider discontinuing
anticholinergic medications; replace
anticholinergics with alternative
treatment, and re-evaluate cognition
with full cognitive assessment within
three months    
Delirium assessment:
CAM/CAM-ICU 
Global cognitive assessment:
TICS, MMSE  
Figure 2 Proposed algorithm for the clinical approach to older adults prescribed anticholinergic medications.
Abbreviations: CAM, Confusion Assessment Method;   TICs, telephone interview for cognitive status; MMse, Mini-Mental status exam.
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an acute illness, is uniquely sensitive to the central 
anticholinergic adverse effects of medications and should be 
closely monitored for the development of unwanted adverse 
effects on cognition. Recognizing patients at risk due to 
exposure of anticholinergics should warrant cognitive evalu-
ation not only in acute care environments, but also ambula-
tory environments when subjective complaints of cognitive 
impairment supplement clinical suspicion. In clinical practice 
situations where anticholinergic cognitive adverse effects 
are suspected, the course of action might be to consider the 
withdrawal of potentially offending medication(s). Although 
the expected clinical impact on cognitive deficits with a 
reduction in anticholinergic burden remains to be sufficiently 
studied, removal of potentially harmful medications in lieu 
of equally effective alternatives with lower anticholinergic 
activity might be a good practice.
Scenario resolution
During the hospitalization, the patient received a geriatrics 
consultation and her anticholinergics burden was reduced by 
discontinuing ranitidine, oxybutynin, diphenhydramine, and 
digoxin. Ranitidine was replaced with esomeprazole, Tyle-
nol PM® was replaced with acetaminophen as needed, and 
no replacements were instituted for oxybutynin and digoxin. 
Other medications with notable systemic anticholinergic 
properties, warfarin and atenolol, were continued during 
the hospital stay and at discharge. The patient’s delirium 
resolved within 48 hours of hospital admission due to either 
resolving medical illness or a reduction of anticholinergic 
burden. Repeat MMSE was not performed, though follow-up 
for further cognitive testing was arranged within four weeks 
after discharge, where mild cognitive impairment was identi-
fied and the patient continues to follow in the geriatric clinic 
for appropriate monitoring of cognitive function.
Conclusion
In a world facing an exponential growth of older patients, 
high prevalence of multiple chronic disease and substantial 
use of numerous medications, the integration of a routine 
recognition of the anticholinergic cognitive effects of 
medications into the care of hospitalized older adults may 
have the potential to improve patient and health care-related 
outcomes.
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